UY35589A - Compuesto peptídico - Google Patents

Compuesto peptídico

Info

Publication number
UY35589A
UY35589A UY0001035589A UY35589A UY35589A UY 35589 A UY35589 A UY 35589A UY 0001035589 A UY0001035589 A UY 0001035589A UY 35589 A UY35589 A UY 35589A UY 35589 A UY35589 A UY 35589A
Authority
UY
Uruguay
Prior art keywords
leu
peptide compound
tyr
glu
thr
Prior art date
Application number
UY0001035589A
Other languages
English (en)
Inventor
Asami Taiji
Niida Ayumu
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY35589A publication Critical patent/UY35589A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto peptídico novedoso que ejerce una acción de activación sobre los receptores del GLP-1 y los receptores del GIP,así como el uso del compuesto peptídico como medicamento.Específicamente, se proporcionan un péptido que contiene una secuencia parcial representada por la fórmula (I) o una sal de él y un medicamento que lo comprende. P1-Tyr-Aib-Glu-Gly-Thr-¿MePhe-Thr-Ser-Asp-Tyr-A11-A12-A13-Leu-Asp-A16-A17-Ala-Gln-A20-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-A29 en donde cada símbolo tiene el significado definido en la presente.
UY0001035589A 2013-05-28 2014-05-27 Compuesto peptídico UY35589A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013111893 2013-05-28

Publications (1)

Publication Number Publication Date
UY35589A true UY35589A (es) 2014-12-31

Family

ID=50942304

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035589A UY35589A (es) 2013-05-28 2014-05-27 Compuesto peptídico

Country Status (36)

Country Link
US (2) US9200051B2 (es)
EP (1) EP3004155B1 (es)
JP (2) JP6429799B2 (es)
KR (1) KR102229051B1 (es)
CN (1) CN105209485B (es)
AP (1) AP2015008781A0 (es)
AR (1) AR096440A1 (es)
AU (1) AU2014272500B2 (es)
CA (1) CA2908581C (es)
CL (1) CL2015003031A1 (es)
CY (1) CY1124790T1 (es)
DK (1) DK3004155T3 (es)
DO (1) DOP2015000261A (es)
EA (2) EA035813B1 (es)
EC (1) ECSP15044389A (es)
ES (1) ES2900744T3 (es)
GE (1) GEP201706762B (es)
HK (1) HK1216757A1 (es)
HR (1) HRP20212014T1 (es)
HU (1) HUE057361T2 (es)
IL (1) IL242005B (es)
LT (1) LT3004155T (es)
MA (1) MA38472B1 (es)
MX (2) MX2015015464A (es)
MY (1) MY172744A (es)
PE (1) PE20151770A1 (es)
PH (1) PH12015502391B1 (es)
PL (1) PL3004155T3 (es)
PT (1) PT3004155T (es)
SG (1) SG11201507934PA (es)
SI (1) SI3004155T1 (es)
TN (1) TN2015000451A1 (es)
TW (1) TWI638831B (es)
UA (1) UA118558C2 (es)
UY (1) UY35589A (es)
WO (1) WO2014192284A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2900744T3 (es) 2013-05-28 2022-03-18 Takeda Pharmaceuticals Co Compuesto de péptidos
JOP20200119A1 (ar) 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
CN104846061A (zh) * 2015-05-07 2015-08-19 中国药科大学 一种glp-1受体激动剂的受体亲和力测定方法
CN105388239B (zh) * 2015-12-18 2018-01-05 兆科药业（合肥）有限公司 一种多肽固相合成的监测方法
CA3024962A1 (en) * 2016-05-24 2017-11-30 Takeda Pharmaceutical Company Limited Peptide compound
US11285180B2 (en) 2016-12-06 2022-03-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
JOP20180028A1 (ar) * 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
WO2019140030A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
KR20200132852A (ko) * 2018-01-23 2020-11-25 길라 테라퓨틱스, 인코포레이티드 펩티드 yy 약학적 제형, 조성물, 및 방법
JP6818940B2 (ja) 2018-05-04 2021-01-27 ノヴォ ノルディスク アー／エス Ｇｉｐ誘導体およびその使用
CN110818771B (zh) * 2018-08-14 2023-01-17 陈铭 使用氨基酸离子液体的羰基硫介导多肽合成
JP2022503793A (ja) * 2018-09-24 2022-01-12 武田薬品工業株式会社 Ｇｉｐ受容体アゴニストペプチド化合物及びその使用
EP3856339A1 (en) * 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
AU2020334993B2 (en) * 2019-08-19 2023-07-13 Eli Lilly And Company Methods of making incretin analogs
EP4043026A4 (en) 2019-10-04 2024-01-10 Hanmi Pharm. Co., Ltd. GLUCAGON, GLP-1 RECEPTOR AND DGIP RECEPTOR DUAL AGONIST COMPOSITION AND THERAPEUTIC USE THEREOF
CN110684082B (zh) 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
KR20230005184A (ko) * 2020-03-25 2023-01-09 다케다 야쿠힌 고교 가부시키가이샤 Gip 수용체 작용제 펩티드 화합물의 qd 투약 및 이의 용도
JP2023534130A (ja) 2020-07-22 2023-08-08 ノヴォ ノルディスク アー／エス Ｇｌｐ－１受容体およびｇｉｐ受容体共作動薬
MX2023000303A (es) 2020-07-22 2023-02-09 Novo Nordisk As Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.
EP4345105A1 (en) 2021-06-01 2024-04-03 Nanjing Zhine Medicine Technology Co., Ltd. Polypeptide derivative having effect of dual targeted activation of glp-1r and gipr, preparation method therefor, and use thereof
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
WO2024012472A1 (zh) * 2022-07-13 2024-01-18 杭州中美华东制药有限公司 Glp-1/gip双激动剂及其制备方法和用途
WO2024059674A1 (en) 2022-09-15 2024-03-21 Eli Lilly And Company Gip and glp-1 dual agonist compounds
WO2024141760A1 (en) 2022-12-30 2024-07-04 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
ATE289517T1 (de) 1996-11-12 2005-03-15 Novo Nordisk As Verwendung von glp-1 peptiden
AU3087599A (en) 1998-03-19 1999-10-11 Bionebraska, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
EP1306091A3 (en) 1998-07-31 2003-05-21 Novo Nordisk A/S Stimulation of beta cell proliferation
IL143481A0 (en) 1998-12-07 2002-04-21 Sod Conseils Rech Applic Glp-1 analogues
US20030157107A1 (en) 2000-05-16 2003-08-21 Kazumasa Miyawaki Agents for preventing or ameliorating insulin resistance and/or obesity
AU2003243929B2 (en) 2002-07-04 2009-06-04 Zp Holding Spv K/S GLP-1 and methods for treating diabetes
EP2210900A3 (en) 2003-12-16 2010-08-11 Ipsen Pharma Analogues of GLP-1
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
WO2006136374A2 (en) 2005-06-20 2006-12-28 Develogen Aktiengesellschaft Use of gip and/or vitamin d3 analogues thereof for enhancing stem or progenitor cell differentiation into insulin producing cells
US20080015265A1 (en) 2006-07-11 2008-01-17 Byron Rubin Methods of treating obesity using satiety factors
JP5399244B2 (ja) 2006-08-17 2014-01-29 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 選択可能な特性を持つｄｐｐ−ｉｖ耐性ｇｉｐハイブリッドポリペプチド
TWI430806B (zh) 2006-09-13 2014-03-21 Smithkline Beecham Corp 用於投與長效降血糖藥劑之方法
EP1972349A1 (en) 2007-03-21 2008-09-24 Biocompatibles UK Limited GLP-1 fusion peptides conjugated to polymer(s), their production and use
WO2009067268A1 (en) 2007-11-23 2009-05-28 Michael Rothkopf Methods of enhancing diabetes resolution
EP2300035B1 (en) 2008-06-17 2015-08-12 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
MX339137B (es) 2008-08-07 2016-05-13 Ipsen Pharma Sas Analogos de polipeptidos insulinotropicos dependientes de glucosa (gip) modificados en n terminal.
ES2620610T3 (es) 2008-12-10 2017-06-29 Glaxosmithkline Llc Composiciones farmacéuticas de albiglutide
SG176858A1 (en) 2009-06-16 2012-02-28 Univ Indiana Res & Tech Corp Gip receptor-active glucagon compounds
US9260500B2 (en) 2009-07-02 2016-02-16 Takeda Pharmaceutical Company Limited Peptide and use thereof
EP2528618A4 (en) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
EP2654774A4 (en) 2010-12-22 2015-07-01 Marcadia Biotech Inc METHOD FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS WITH GIP AND GLP-1 RECEPTOR ACTIVE PUCIDIDES ON GLUCAGON BASIS
WO2012138941A1 (en) 2011-04-05 2012-10-11 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
EP2718317B1 (en) 2011-06-10 2018-11-14 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
KR102066987B1 (ko) 2011-06-10 2020-01-16 노보 노르디스크 에이/에스 폴리펩티드
US20130090285A1 (en) 2011-06-27 2013-04-11 Phasebio Pharmaceuticals, Inc. Methods of treatment with glp-1 receptor agonists
US9758560B2 (en) 2011-09-06 2017-09-12 Novo Nordisk A/S GLP-1 derivatives
EP2830646B1 (en) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
CN104519902B (zh) 2012-05-08 2017-10-27 诺和诺德股份有限公司 双酰化glp‑1衍生物
US20150182461A1 (en) 2012-06-19 2015-07-02 Massachussets Institute Of Technology Mass Production and Size Control of Nanoparticles Through Controlled Microvortices
CA2877127A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Analogs of glucagon exhibiting gip receptor activity
RU2015101697A (ru) 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, обладающие активностью рецептора gip
CN104968674A (zh) 2012-12-19 2015-10-07 诺和诺德股份有限公司 具有胆固醇流出活性的新颖的glp-1受体激动剂
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
US9714277B2 (en) 2013-03-14 2017-07-25 Medimmune Limited Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity
ES2900744T3 (es) 2013-05-28 2022-03-18 Takeda Pharmaceuticals Co Compuesto de péptidos
KR102310392B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
JP2018012644A (ja) 2014-11-26 2018-01-25 武田薬品工業株式会社 ペプチド化合物

Also Published As

Publication number Publication date
SI3004155T1 (sl) 2022-02-28
US10087229B2 (en) 2018-10-02
CL2015003031A1 (es) 2016-06-24
JP2016520511A (ja) 2016-07-14
WO2014192284A1 (en) 2014-12-04
CA2908581A1 (en) 2014-12-04
KR102229051B1 (ko) 2021-03-16
CN105209485A (zh) 2015-12-30
AP2015008781A0 (en) 2015-10-31
NZ712421A (en) 2021-04-30
US20140357552A1 (en) 2014-12-04
GEP201706762B (en) 2017-10-25
CA2908581C (en) 2021-07-13
MA38472A1 (fr) 2018-01-31
PE20151770A1 (es) 2015-12-11
LT3004155T (lt) 2021-12-27
CN105209485B (zh) 2019-12-10
JP2018168167A (ja) 2018-11-01
JP6429799B2 (ja) 2018-11-28
PH12015502391A1 (en) 2016-02-22
CY1124790T1 (el) 2022-11-25
HRP20212014T1 (hr) 2022-04-01
MX2015015464A (es) 2016-03-21
EA202090593A2 (ru) 2020-06-30
BR112015027596A2 (pt) 2017-12-05
HK1216757A1 (zh) 2016-12-02
JP6570705B2 (ja) 2019-09-04
EA202090593A3 (ru) 2020-08-31
HUE057361T2 (hu) 2022-05-28
AR096440A1 (es) 2015-12-30
TN2015000451A1 (en) 2017-04-06
US9200051B2 (en) 2015-12-01
EA035813B1 (ru) 2020-08-14
ECSP15044389A (es) 2017-08-31
PT3004155T (pt) 2021-12-22
EP3004155A1 (en) 2016-04-13
SG11201507934PA (en) 2015-10-29
TWI638831B (zh) 2018-10-21
TW201514203A (zh) 2015-04-16
US20160052988A1 (en) 2016-02-25
MY172744A (en) 2019-12-11
PH12015502391B1 (en) 2016-02-22
AU2014272500B2 (en) 2018-03-08
PL3004155T3 (pl) 2022-02-07
EP3004155B1 (en) 2021-11-24
EA201591891A1 (ru) 2016-01-29
ES2900744T3 (es) 2022-03-18
MX2019010531A (es) 2019-10-15
KR20160010446A (ko) 2016-01-27
MA38472B1 (fr) 2018-09-28
DK3004155T3 (da) 2022-01-03
UA118558C2 (uk) 2019-02-11
AU2014272500A1 (en) 2015-11-05
IL242005B (en) 2019-05-30
DOP2015000261A (es) 2015-12-31

Similar Documents

Publication Publication Date Title
UY35589A (es) Compuesto peptídico
AR111346A1 (es) Compuesto peptídico con acción activante sobre receptores gip
DOP2016000206A (es) Compuesto heterocíclico fusionado
ECSP18053055A (es) Agonista triple de receptores de glucagón/glp-1/gip
UY35995A (es) Compuesto heterocíclico
CL2017002452A1 (es) Nuevos compuestos bicíclicos
IT201700090078A1 (it) Maschera per uso subacqueo, in particolare di tipo granfacciale dotata di dispositivo di comunicazione.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CR20160257A (es) Anticuerpos e inmunoconjugados anti-cd33
UA122767C2 (uk) Ацильований аналог глюкагону
CR20160419A (es) Nuevos compuestos biciclicos
CR20130447S (es) Botella
UY35774A (es) Compuesto heterocíclico
AR128158A2 (es) Compuesto heterocíclico
ES2721400T3 (es) Composición de Diclofenaco
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
AR099132A1 (es) Colorante-polímero
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
UY36150A (es) Derivados de naftiridinadiona
CR20150642A (es) Preparado farmaceutico
UY35650A (es) Compuesto heterocíclico
CR20150533A (es) Compuesto peptídico
BR102014007923A8 (pt) sistema nanoestruturado polimérico e seu uso
CR20130615S (es) Contenedor
GT201700022S (es) Botella caraïbes

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211206